Redbiotec completes proof of concept study
Intercell and Redbiotec have successfully completed the proof of concept study, in which Redbiotec has applied its proprietary technology platform rePAX in an undisclosed discovery area. Redbiotec looks forward to continue its collaboration with Intercell.
Redbiotec uses its proprietary rePAX co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies. The company entered the field of VLP vaccines in 2008 and currently has a pipeline in the areas of CMV, HPV and Influenza. Besides developing its own prophylactic VLP vaccine pipeline, the company also offers customized solutions in Biologics to selected Partners.
The company announced yesterday that it has successfully completed a proof of concept study in cooperation with Intercell, in which Redbiotec has applied its proprietary technology platform rePAX in an undisclosed discovery area. Redbiotec looks forward to continue its collaboration with Intercell.
Redbiotec is a privately held Swiss Biopharmaceutical Company, based in Zurich-Schlieren. Founded in 2006 as a spin-off of the ETH Zurich, the company won several prizes, including the renowned W.A. De Vigier award.
Intercell is an innovative biotechnology company focused on the design and development of novel vaccines for the prevention and treatment of infectious diseases. The company, headquartered in Vienna, is listed on the Vienna Stock Exchange
Please login or sign up to comment.
Commenting guidelines